Determinants of bare-metal stent use in patients with ST-elevation myocardial infarction undergoing primary

Puja B Parikh1, Allen Jeremias, Srihari S Naidu

  • 1Department of Medicine, Division of Cardiovascular Diseases, Health Sciences Center, T16-080, Stony Brook, NY 11794-8160 USA.

Insights

Patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction were more likely to receive bare-metal stents (BMS) if uninsured, had peripheral vascular disease, or worse left ventricular ejection fraction (LVEF). These factors predict BMS use in STEMI patients.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Health Services Research

Background:

  • Bare-metal stent (BMS) use in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) is linked to increased adverse cardiac events.
  • Understanding predictors of BMS use is crucial for optimizing patient care and outcomes in STEMI.

Purpose of the Study:

  • To identify clinical characteristics that predict the use of BMS versus drug-eluting stents (DES) in patients with STEMI undergoing primary PCI.

Main Methods:

  • Prospective data collection from 1394 STEMI patients undergoing primary PCI across four New York State academic medical centers (2004-2007).
  • Comparison of demographics, medical history, procedural details, and in-hospital outcomes between BMS and DES groups.
  • Multivariate analysis to determine independent predictors of BMS implantation.

Main Results:

  • 20.8% of patients received BMS (n=290), while 79.2% received DES (n=1104).
  • BMS recipients had higher rates of prior coronary artery bypass graft surgery, peripheral vascular disease, diabetes, Hispanic ethnicity, and were more likely to be uninsured.
  • Independent predictors for BMS use included uninsured status (OR, 2.81), peripheral vascular disease (OR, 1.96), and lower left ventricular ejection fraction (LVEF) (OR, 0.98).

Conclusions:

  • In STEMI patients undergoing primary PCI, lack of health insurance, presence of peripheral vascular disease, and reduced LVEF are independently associated with higher likelihood of BMS implantation.
  • These findings highlight socioeconomic and clinical factors influencing stent selection in acute myocardial infarction.

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...